ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

NFX Nuformix Plc

0.185
-0.005 (-2.63%)
01 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Nuformix Plc LSE:NFX London Ordinary Share GB00BYW79Y38 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.005 -2.63% 0.185 0.17 0.20 0.18 0.17 0.18 7,588,545 16:35:30
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -859k -0.0012 -1.42 1.27M
Nuformix Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker NFX. The last closing price for Nuformix was 0.19p. Over the last year, Nuformix shares have traded in a share price range of 0.17p to 0.44p.

Nuformix currently has 744,309,368 shares in issue. The market capitalisation of Nuformix is £1.27 million. Nuformix has a price to earnings ratio (PE ratio) of -1.42.

Nuformix Share Discussion Threads

Showing 7151 to 7172 of 9525 messages
Chat Pages: Latest  297  296  295  294  293  292  291  290  289  288  287  286  Older
DateSubjectAuthorDiscuss
20/1/2021
21:18
Nope, just over £2k buys today vs. £13,600 sells
soupdragon55
20/1/2021
20:44
Did I read it right ? £12 worth purchased today !!
jackpotjoywinner
20/1/2021
07:51
Any posts on your thread yet Jamie?
soupdragon55
18/1/2021
00:26
I assumed that they were odd pseudonyms for David Topalczay & Joanne Holland.So we've even drawn a blank there too. Outstanding!
for fx sake
17/1/2021
23:47
Looking further at the supporting documents, its actually a bizarre coincidence!

Looks like the inventor is actually a David T Joanitis of Brookston Indiana.





So not actually sure now if this patent would relate to NFX???

soupdragon55
17/1/2021
23:23
Joanitis? Sounds more like something it might be used to treat.Ebers have always seemed to be a very strange and secretive outfit. Their website ranks possibly as one the most informative I've ever seen, not.Let's just hope they pay their dues if and when the cashola starts to roll in.
for fx sake
16/1/2021
00:19
Simple simon and his multiple aliases lolNot hard to spot! Have a good weekend!
jamie414
15/1/2021
15:38
I could kick myself I bought more yesterday !
carlisle44
14/1/2021
23:12
It means Ebers will raise cash, they can then pay for more patent work from NFX. After that they can pay for development of the product and pay NFX milestones as per the £51m contract, then royalties follow.

Ebers sole business plan uses NFX to generate the IP.

soupdragon55
14/1/2021
22:07
Thanks for the response soup. However how does that affect nfx? Can you simplify please? And will this mean we are moving forward?
jackpotjoywinner
14/1/2021
21:08
Jackpot,

NFX movement today caused by us finding out Ebers Tech are reversing into TSX listed Kelly Ventures raising $53m.




2020-12-21 16:37 ET - News Release


Mr. Paul Larkin reports

KELLY VENTURES TO ACQUIRE EBERS TECH INC. AS QUALIFYING TRANSACTION

Kelly Ventures Ltd. has signed a letter of intent (LOI), dated Dec. 18, 2020, pursuant to which the company will acquire all of the outstanding shares of Ebers Tech Inc. The parties intend to complete a business combination or other similarly structured transaction which will constitute a reverse takeover of Kelly Ventures. The proposed transaction is intended to be an arm's-length qualifying transaction (QT) for the company as defined under TSX Venture Exchange policies.

Ebers is a Canadian-registered pharma tech company, with a portfolio of patents and development methods for producing cocrystals. Ebers is strategically positioned at the nexus of the big pharmaceutical and cocrystal industries, enabling the company to play a crucial role in the development of the next generation of pharmaceuticals and therapies and to simultaneously exploit the rapidly advancing cannabinoid and psilocybin cocrystal, pharmaceutical and wellness areas. Of these, the most widely studied and used application is in drug development and, more specifically, the formation, design and implementation of active pharmaceutical ingredients (API).

soupdragon55
14/1/2021
20:29
I used to post on lse but I'm unable to sign in the char room. I'm guessing jay12 or offshore sailor got a grudge ...any reason why nfx is moving up today?
jackpotjoywinner
14/1/2021
18:22
First time user here.. can you tell me why the share has increased today ? Is it a Twitter pump and dump attack yet again?
jackpotjoywinner
14/1/2021
14:55
You may just have deployed the defibrillator :0)
for fx sake
14/1/2021
14:50
Glad this has brightened up everyone's day
soupdragon55
14/1/2021
14:43
Might hit 12p this week.
hodhasharon
14/1/2021
14:37
Well that didn't take long
for fx sake
14/1/2021
14:21
Any idea how dependent Ebers is on NFX (i.e how much of 53m valuation is down to NFX co-crystal IP)?
for fx sake
14/1/2021
14:18
Good research Soup. Can't wait to see how the Twitterati react.
for fx sake
14/1/2021
13:21
For balance as I post elsewhere.

Ebers Tech are reversing into TSX listed Kelly Ventures raising $53m.




2020-12-21 16:37 ET - News Release


Mr. Paul Larkin reports

KELLY VENTURES TO ACQUIRE EBERS TECH INC. AS QUALIFYING TRANSACTION

Kelly Ventures Ltd. has signed a letter of intent (LOI), dated Dec. 18, 2020, pursuant to which the company will acquire all of the outstanding shares of Ebers Tech Inc. The parties intend to complete a business combination or other similarly structured transaction which will constitute a reverse takeover of Kelly Ventures. The proposed transaction is intended to be an arm's-length qualifying transaction (QT) for the company as defined under TSX Venture Exchange policies.

Ebers is a Canadian-registered pharma tech company, with a portfolio of patents and development methods for producing cocrystals. Ebers is strategically positioned at the nexus of the big pharmaceutical and cocrystal industries, enabling the company to play a crucial role in the development of the next generation of pharmaceuticals and therapies and to simultaneously exploit the rapidly advancing cannabinoid and psilocybin cocrystal, pharmaceutical and wellness areas. Of these, the most widely studied and used application is in drug development and, more specifically, the formation, design and implementation of active pharmaceutical ingredients (API).

soupdragon55
13/1/2021
14:48
Looks like it
frogyboyo
13/1/2021
12:05
? Jamie being a nonce again?
frogyboyo
Chat Pages: Latest  297  296  295  294  293  292  291  290  289  288  287  286  Older

Your Recent History

Delayed Upgrade Clock